Description

Domperidone Film-Coated / Mouth Dissolving Tablets (10 mg)

Healthy Inc is a specialized global supplier and exporter of advanced gastroenterology, prokinetic, and targeted antiemetic therapeutics. We provide ultra-high-purity, kinetically optimized Domperidone Film-Coated and Mouth Dissolving (MD) Tablets (10 mg), manufactured in WHO–GMP certified, high-precision rapid-release oral solid dosage facilities. This “Peripheral D2-Receptor Antagonist” is a massive-volume, highly strategic export to gastroenterology networks, oncology palliative care centers, pediatric clinics, and government health ministries in LATAM, the CIS, Africa, and Southeast Asia, serving as the globally mandated, non-sedating intervention for acute nausea, vomiting, and severe diabetic gastroparesis.

Product Overview

This highly advanced formulation operates as a sophisticated, dual-action gastrointestinal regulator. It chemically silences the brain’s vomiting center while simultaneously forcing the stomach and upper intestines to contract, physically pushing food downward and clearing the gastric tract.

The “Peripheral D2 Antagonist & Prokinetic” Specialist:

• Mechanism 1 (The Chemoreceptor Trigger Zone Blockade): Domperidone acts as a highly selective antagonist at Dopamine D2 receptors. It specifically targets the Chemoreceptor Trigger Zone (CTZ), a unique area in the medulla oblongata that is located outside the blood-brain barrier. By blocking dopamine from binding here, it instantly neutralizes the chemical signals that trigger severe nausea and the physical vomiting reflex.
• Mechanism 2 (The Upper GI Prokinetic Drive): In the stomach and upper duodenum, blocking D2 receptors prevents dopamine from inhibiting gastric motility. This dramatically accelerates gastric emptying, increases lower esophageal sphincter (LES) tone, and enhances gastroduodenal coordination. It physically forces stagnant food out of the stomach, providing rapid relief for bloating, fullness, and dyspepsia.
• Mechanism 3 (The Blood-Brain Barrier Exclusion): The defining clinical advantage of Domperidone over older antiemetics (like Metoclopramide) is its molecular inability to cross the blood-brain barrier in significant amounts. This guarantees that patients experience profound relief from nausea with absolutely zero risk of central nervous system (CNS) side effects, such as extreme sedation, acute dystonic reactions, or drug-induced Parkinsonism.

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Gastroenterology Distributors, and Hospital Procurement Boards.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Impurity Profiling & Cardiac Compliance (CRITICAL): Due to the global regulatory scrutiny regarding Domperidone and cardiac arrhythmias, the API must be flawlessly synthesized. Our GI suites utilize advanced HPLC analytical testing to guarantee that absolutely zero cardiotoxic impurities exist within the formulation. We strictly adhere to the updated European Medicines Agency (EMA) guidelines, ensuring our 10mg tablets are engineered perfectly for the newly mandated short-term, low-dose safety protocols.

Therapeutic Indications (Human Use)

Indicated for the targeted, highly specialized symptomatic management of gastrointestinal distress:

• Acute Nausea & Vomiting: Rapid relief of nausea and vomiting of various etiologies (including post-operative, infectious, or migraine-induced).
• Diabetic Gastroparesis: Management of severe delayed gastric emptying, bloating, and early satiety in diabetic patients.
• Functional Dyspepsia: Relief of upper abdominal discomfort, feeling of fullness, and regurgitation of gastric contents.

Dosage & Administration

Recommended Dosage (Strictly as per Updated Regulatory Guidelines):

• Standard Adult Dosing: 10 mg taken orally up to three times a day.
• The Maximum Limit Mandate (CRITICAL): The maximum daily dose MUST NOT exceed 30 mg. Therapy should be restricted to the shortest possible duration (typically not exceeding one week).
• Administration: Must be taken 15 to 30 minutes before meals. Taking it after meals severely delays the drug’s absorption and blunts its prokinetic effect.

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• BLACK BOX EQUIVALENT (QTc Prolongation & Sudden Cardiac Death): Domperidone is associated with an increased risk of severe cardiac arrhythmias, QTc prolongation, and sudden cardiac death, particularly in patients over 60 years old or those taking doses exceeding 30 mg daily. It is strictly contraindicated in patients with known prolonged cardiac conduction intervals or underlying cardiac disease.
• CYP3A4 Inhibitor Contraindication (FATAL): It is strictly contraindicated to co-administer Domperidone with potent CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin, Clarithromycin). These drugs block the liver from clearing Domperidone, causing blood levels to spike violently and triggering fatal cardiac arrest.
• Hyperprolactinemia: Because dopamine normally inhibits prolactin release, blocking D2 receptors causes prolactin levels to surge. This can lead to galactorrhea (abnormal breast milk production), gynecomastia (breast enlargement in men), and amenorrhea (absence of menstruation).
• Hepatic Impairment: Contraindicated in patients with moderate or severe hepatic impairment.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving international Pharma Traders, Wholesalers, and Gastroenterology Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Antiemetics, Prokinetics, and Rapid-Burst MD Tableting Formulations. Whether you are looking for a reliable Government Tender Supplier for GI clinics in Africa or a B2B Pharma Marketplace partner for Southeast Asia, our highly regulated logistics network ensures timely, secure delivery of WHO-GMP certified products.